Tilly Metz, Member of the European Parliament, shared a post on LinkedIn:
“What if cancer treatment could be not just more effective, but also gentler, fairer, and more sustainable?
This week at the European Parliament, I had the honour to open an important discussion on treatment optimisation alongside patients, researchers, and healthcare professionals.
Cancer remains one of our greatest collective challenges. And part of that challenge lies in the treatments themselves: too often, they reach patients without enough long-term evidence on side effects or optimal dosing.
We can do better. And we must do better.
Because this isn’t only about survival: it’s about quality of life, equity, and the sustainability of our healthcare systems.
The white paper we launched calls for a shift in how we evaluate treatments: by optimising them. That means adjusting dose, reducing treatment when safe, avoiding unnecessary toxicities, and improving patients’ well-being.
There are still regulatory, ethical, and commercial barriers. But promising trials show that progress is possible.
The ongoing revision of EU pharmaceutical legislation is a key opportunity to make cancer care more compassionate, more affordable, and more effective.
Grateful to EORTC – European Organisation for Research and Treatment of Cancer for organising this event, and to Romana Jerković for co-hosting.”
More from Tilly Metz on OncoDaily.
